Concepedia

Oliver Schadt

OS

6

Publications

337

Citations

6

H-Index

2012

Active since

Affiliations

Merck (Germany)(Current)

Oliver Schadt is an author at Merck (Germany) specializing in medicine, biochemistry, and natural sciences.

ORCID

Top concepts

Publications per year

2012–2021

6

Publications

6

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

Friedhelm Bladt, Bettina Faden, Manja Friese‐Hamim et al. · Clinical Cancer Research · 2013 · 138 citations · Full text

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors

Dieter Dorsch, Oliver Schadt, Frank Stieber et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 88 citations · Full text

, , +7

M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models

Michael P. Sanderson, Manja Friese‐Hamim, Gina Walter-Bausch et al. · Molecular Cancer Therapeutics · 2021 · 36 citations · Full text

Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)

Markus Klein, Michael Busch, Manja Friese‐Hamim et al. · Journal of Medicinal Chemistry · 2021 · 35 citations · Full text

Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics

Jeffery Chakedis, Randall P. French, Michele Babicky et al. · Oncotarget · 2016 · 28 citations · Full text

, , +17

Rows per page

1–5 of 6